
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington, D.C. - Because all the ramifications of new medications - and even some of the older ones - are not yet known, practitioners should give special consideration to possible side effects. In making treatment decisions, get as much information as possible, said Roselyn E. Epps, M.D.